Miss a day, miss a lot. Subscribe to The Defender's Top News of the Day. It's free.
The Centers for Disease Control and Prevention (CDC) today released new data showing a total of 1,217,333 reports of adverse events following COVID vaccines were submitted between Dec. 14, 2020, and April 1, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.
The data included a total of 26,699 reports of deaths — an increase of 303 over the previous week — and 217,301 of serious injuries, including deaths, during the same time period — up 2,780 compared with the previous week.
Foreign reports are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product’s labeling, the manufacturer is required to submit the report to VAERS.
Of the 12,304 U.S. deaths reported as of April 1, 17% occurred within 24 hours of vaccination, 21% occurred within 48 hours of vaccination and 59% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 561 million COVID vaccine doses had been administered as of April 1, including 331 million doses of Pfizer, 211 million doses of Moderna and 19 million doses of Johnson & Johnson (J&J).
Every Friday, VAERS publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.
Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.
U.S. VAERS data from Dec. 14, 2020, to April 1, 2022, for 5- to 11-year-olds show:
- 10,157 adverse events, including 239 rated as serious and 5 reported deaths.
The most recent death involves a 7-year-old boy (VAERS I.D. 2152560) from Washington who died 13 days after receiving his first dose of Pfizer’s COVID vaccine when he went into shock and suffered cardiac arrest. He was unable to be resuscitated and died in the emergency department.
- 17 reports of myocarditis and pericarditis (heart inflammation).
The CDC uses a narrowed case definition of “myocarditis,” which excludes cases of cardiac arrest, ischemic strokes and deaths due to heart problems that occur before one has the chance to go to the emergency department.
- 38 reports of blood clotting disorders.
U.S. VAERS data from Dec. 14, 2020, to April 1, 2022, for 12- to 17-year-olds show:
- 30,954 adverse events, including 1,778 rated as serious and 44 reported deaths.
The most recent death reported to VAERS involves a 15-year-old girl (VAERS I.D. 2201554) from South Dakota who developed COVID despite receiving two doses of the Pfizer/BioNTech. She received her first dose of Pfizer on July 30, 2021, and her second dose on August 20, 2021. She presented to the ER on January 15, 2022, with abdominal pain, tested positive for COVID, was put on a ventilator and subsequently passed away.
- 68 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death — with 96% of cases attributed to Pfizer’s vaccine.
- 650 reports of myocarditis and pericarditis, with 638 cases attributed to Pfizer’s vaccine.
- 165 reports of blood clotting disorders, with all cases attributed to Pfizer.
U.S. VAERS data from Dec. 14, 2020, to April 1, 2022, for all age groups combined, show:
- 20% of deaths were related to cardiac disorders.
- 54% of those who died were male, 41% were female and the remaining death reports did not include the gender of the deceased.
- The average age of death was 73.
- As of April 1, 5,370 pregnant women reported adverse events related to COVID vaccines, including 1,693 reports of miscarriage or premature birth.
- Of the 3,642 cases of Bell’s Palsy reported, 51% were attributed to Pfizer vaccinations, 40% to Moderna and 8% to J&J.
- 878 reports of Guillain-Barré syndrome, with 42% of cases attributed to Pfizer, 30% to Moderna and 28% to J&J.
- 2,377 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 1,666 reports of myocardial infarction.
- 13,738 reports of blood-clotting disorders in the U.S. Of those, 6,145 reports were attributed to Pfizer, 4,899 reports to Moderna and 2,651 reports to J&J.
- 4,099 cases of myocarditis and pericarditis with 2,517 cases attributed to Pfizer, 1,391 cases to Moderna and 180 cases to J&J’s COVID vaccine.
34-year-old dies two weeks after Pfizer vaccine, CDC fails to investigate
A 34-year-old man died suddenly just two weeks after receiving his first dose of Pfizer’s COVID vaccine from an acute aortic dissection — an uncommon medical emergency in which the inner layer of the large blood vessel branching off the heart’s aorta tears. The condition mostly affects men in their 60s and 70s.
In an exclusive interview with The Defender, Victor Castillo Simoes’ mother, Henrietta, said her son’s only symptom was the chest pain he experienced shortly before he died.
After his death, Henrietta said testing ruled out genetic factors that could have caused the heart condition, and a prestigious researcher working with the family shared her suspicion the vaccine triggered the event.
Henrietta on Sept. 9, reported her son’s death to VAERS. The CDC offered its condolences but did not investigate Simoes’ death.
According to the VAERS website, the CDC follows up only on reports classified as serious by “attempting to obtain medical records to better understand the event.”
In the case of many vaccine injury stories reported by The Defender — including Simoes’ — medical records are not available for those who suddenly die after receiving a COVID vaccine and did not make it to a hospital for treatment.
According to the VAERS website, this means the CDC is not following up on these reported deaths.
FDA vaccine advisors discuss waning vaccine efficacy, ignore vaccine-injured
The FDA’s vaccine advisory panel met Wednesday to discuss second booster doses of COVID vaccines for the American public.
After nine-and-a-half hours, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) failed to reach a consensus, even though last week both the CDC and FDA quietly authorized an additional booster for people over age 50 and the immunocompromised.
During the meeting, committee members determined a second booster dose might be effective — but they weren’t sure for how long. The panel didn’t know how to define effectiveness or when a new vaccine formulation would be needed to address new variants.
It was also revealed a second dose was authorized based on data from Israel that had not been peer-reviewed. The government of Israel offered the second booster to Israelis over age 60 (not 50) at least four months after their third dose and only followed participants for 8 weeks.
Results showed vaccine effectiveness began to wane early after the second booster (four weeks with regard to infection and seven weeks with regard to severe illness).
Severe illness defined in the study was different than the committee’s position, which had always defined severe illness as that which required hospitalization.
Dr. Peter Marks, director of the FDA’s vaccine division, Center for Biologics Evaluation and Research, admitted during the meeting the fourth vaccine dose approved last week was a “stopgap measure” — in other words, a temporary measure to be implemented until a proper solution may be found in the future.
Pfizer secretly hired 600+ people to process vaccine injury reports
Newly released documents obtained via a Freedom of Information Act Request revealed Pfizer hired about 600 additional full-time employees to process adverse event reports during the three months following the Emergency Use Authorization of its COVID-19 vaccine.
The company said it expected to hire a total of 1,800 additional resources by the end of June 2021, according to the documents.
The 10,000-page document cache released April 1 by the FDA showed through Feb. 28, 2021, there were a total of 42,086 case reports (25,379 medically confirmed and 16,707 non-medically confirmed) containing 158,893 adverse events received from 63 countries.
Most reported adverse events were in “System Organ Classes” with reactogenicity events including general disorders and administration site conditions (51,335), nervous system disorders (25,957), musculoskeletal, connective tissue disorders (17,283) and gastrointestinal disorders (14,096).
Despite the findings, Pfizer told the FDA its vaccine was “safe and well-tolerated in healthy adults 18 to 55 years of age, with no unanticipated safety findings.”
Pfizer knew natural immunity was as effective as COVID vaccine
In a discussion with “Rising” co-hosts Robby Soave and Ryan Grim, Kim Iversen identified what she said was the “first bombshell” in the documents: the fact that “natural immunity works, and Pfizer knows it.”
Iversen said clinical trial data showed those with previous COVID infection had no difference in outcome compared to those who were vaccinated.
In the limited trial, none of the vaccinated or those with previous infection experienced severe disease as defined by either the CDC or FDA.
The data also showed infection rates were “statistically identical” among the vaccinated and those with natural immunity.